Treatment-Induced Metabolic and Inflammatory Responses in Cancer

Dear Colleagues,

Radiation therapy, including external beam and internal radionuclide approaches, together with chemotherapy and immunotherapy, forms the cornerstone of contemporary cancer control. Despite substantial advances in treatment delivery and systemic therapies, long-term outcomes are frequently limited by normal tissue toxicity, chronic inflammation, metabolic reprogramming, and the emergence of therapeutic resistance. Growing evidence highlights lipid dysregulation and inflammatory signaling as central mediators linking tumor response, immune modulation, and organ-specific injury across cancers.

This Special Issue aims to provide a comprehensive forum for basic, translational, and clinical studies examining the biological consequences of multimodal cancer therapies. We welcome contributions that explore mechanisms of cancer control, treatment-induced metabolic and inflammatory alterations, and normal tissue injury following radiation, chemotherapy, and immunotherapy. By integrating molecular insights with preclinical and clinical observations, this special issue aims to advance strategies that enhance therapeutic efficacy while mitigating toxicity and improving long-term patient outcomes.

This Special Issue welcomes reviews as well as original research articles, which should be submitted by 15 December 2026.

Dr. Anis Ahmad
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.